Dabrafenib + Trametenib in Anaplastic Thyroid Carcinoma

Dabrafenib + Trametenib in Anaplastic Thyroid Carcinoma

Aleya Tadi L. Garcia, MD; Ria Mari S. Siao, MD Thyroid cancer is the most common endocrine-related malignancy in the